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Abstract 
Introduction: Hypertension is regarded as a condition of mild inflammation and endothelial imbalance. The aim of the study was to evalu-
ate serum concentrations of biomarkers of inflammation and endothelial function: tumour necrosis factor alpha (TNF-a), endothelin-1 
(ET-1), and N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP) in hypertensive and normotensive children.
Material and methods: We studied 63 children aged 13.56 ± 3.73 years, divided into two groups: a group with primary hypertension 
(n = 50) and a group with renal hypertension (n = 13). The control group consisted of 34 normotensive children aged 12.76 ± 3.96 years. 
Biomarkers were measured with ELISA tests.
Results: ET-1 levels were significantly higher in primary hypertension (9.93 ± 1.73 pg/ml) and renal hypertension (10.77 ± 1.50 pg/ml) 
in comparison to controls (4.03 ± 0.97 pg/ml), (p < 0.001, p < 0.001, respectively). NT-pro ANP concentrations in primary hypertension 
(71.03 ± 10.02 pg/ml), and renal hypertension (84.78 ± 6.44 pg/ml) were significantly higher than in the control group (29.62 ± 5.56 
pg/ml) (p < 0.001, p < 0.001, respectively). TNF-a concentrations in primary hypertension (8.36 ± 1.60 pg/ml) and renal hypertension 
(7.35 ± 0.93 pg/ml) significantly exceeded concentrations in controls (4.49 ± 0.93 pg/ml), (p < 0.001, p < 0.001, respectively). ET-1 and 
NT-pro ANP concentrations in renal hypertension significantly exceeded those in primary hypertension (p = 0.049, p < 0.001, respectively) 
while TNF-a levels in renal hypertension were significantly lower than in primary hypertension (p = 0.046).
Conclusions: The results of our study show that ET-1, NT-pro ANP, and TNF-a concentrations are increased in hypertension in children. 
Our investigation indicates significant importance of inflammation and endothelial involvement in hypertension in youth. (Endokrynol 
Pol 2019; 70 (1): 37–42)
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Streszczenie
Wstęp: W rozwoju nadciśnienia tętniczego istotną rolę przypisuje się procesom zapalnym oraz zaburzeniom równowagi śródbłonka 
naczyń. Celem pracy była ocena stężenia markerów stanu zapalnego oraz aktywności śródbłonka: czynnika martwicy nowotworu alfa 
(TNF-a), endoteliny-1 (ET-1) oraz N-końcowego fragmentu przedsionkowego peptydu natriuretycznego (NTpro-ANP) u dzieci z nad-
ciśnieniem tętniczym.
Materiał i metody: W badaniu uczestniczyło 63 dzieci z nadciśnieniem tętniczym w wieku 13,56 ± 3,73 roku, w tym 50 dzieci z rozpozna-
niem pierwotnego nadciśnienia tętniczego oraz 13 dzieci z rozpoznaniem nadciśnienia nerkopochodnego. Grupę kontrolną stanowiło 
34 dzieci w wieku 12,76 ± 3,96 roku z prawidłowym ciśnieniem tętniczym. Stężenia TNF-a, ET-1, NTpro-ANP wykonywano metodą ELISA.
Wyniki: Uzyskano istotnie wyższe stężenia ET-1 w grupie dzieci z pierwotnym nadciśnieniem tętniczym (9,93 ± 1,73 pg/ml) oraz ner-
kopochodnym nadciśnieniem (10,77 ± 1,50 pg/ml) w porównaniu z grupą kontrolną (4,03 ± 0,97 pg/ml) (p < 0,001, p < 0,001). Podobną 
zależność obserwowano dla NT-pro ANP, uzyskując istotnie wyższe stężenie u badanych z pierwotnym nadciśnieniem tętniczym 
(71,03 ± 10,02 pg/ml) oraz nerkopochodnym nadciśnieniem (84,78 ± 6,44 pg/ml) w porównaniu z dziećmi z prawidłowym ciśnieniem 
tętniczym (29,62 ± 5,56 pg/ml) (p < 0,001, p < 0,001). Stężenia TNF-a były istotnie wyższe wśród badanych z pierwotnym nadciśnieniem 
tętniczym (8,36 ± 1,60 pg/ml) oraz nerkopochodnym nadciśnieniem (7,35 ± 0,93 pg/ml) niż u badanych z grupy kontrolnej (4,49 ± 0,93 
pg/ml) (p < 0,001, p < 0,001). U pacjentów z nadciśnieniem nerkopochodnym stężenia ET-1 oraz NT-pro ANP istotnie przewyższały przy 
tym stężenia analogicznych markerów uzyskane u pacjentów z pierwotnym nadciśnieniem tętniczym (p = 0,049, p < 0,001), podczas 
gdy stężenie TNF-a w grupie dzieci z nadciśnieniem nerkopochodnym było istotnie niższe niż u dzieci z pierwotnym nadciśnieniem 
tętniczym (p = 0,046).
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and July 2017, who underwent evaluation according 
to the recommendations of the European Society of 
Hypertension [10]. Office blood pressure (BP) was mea-
sured with the validated oscillometric method with use 
of IntelliVue MX700 device and referred to normative 
data for age, sex, and height provided by the US Task 
Force for children under three years old and by OLAF 
(study on the population of Polish children) for children 
in the age range 3–18 years [11,12]. BP classification 
was based on 2016 European Society of Hypertension 
Guidelines on High Blood Pressure in Children and 
Adolescents: normal BP, systolic blood pressure (SBP), 
and diastolic blood pressure (DBP) < 90th percentile 
for age, sex, and height in a group aged 1-15 years 
and BP < 130/85 mm Hg in a group aged 16 years and 
older; hypertension: 3 BP measurements (on admission 
and two consecutive days) ≥ 95th percentile for age, 
sex, and height in a group aged 1-15 years and SBP 
and/or DBP ≥ 140/90 mmHg in a group aged 16 years 
and older [10]. Patients with hypertension aged five 
years and more and/or with height of minimum 120 
cm underwent ambulatory blood pressure monitoring 
(ABPM) with use of a SunTech device regarding the 95th 
percentile for SBP according to sex, age, and height and 
25% SBP load as thresholds for ambulatory hyperten-
sion [13, 14]. Children with “white coat hypertension” 
were not enrolled in the study. 
Patients with office BP hypertension and ambula-
tory hypertension underwent diagnostic evaluation 
recommended by the European Society of Hyperten-
sion aimed at revealing secondary forms of hyperten-
sion [10]. 
Laboratory tests including plasma creatinine, urea, 
uric acid, electrolytes, fasting glucose, cholesterol, trig-
lycerides, plasma renin activity, aldosterone, thyroid 
function tests, urinalysis and culture, quantification of 
albuminuria, urine metanephrine as well as echocardi-
ography with the assessment of the aortic arch, renal 
ultrasonography, and renal Doppler ultrasonography 
were performed in all patients. Moreover, in obese chil-
dren plasma cortisol was measured. Patients with the 
suspicion of vascular, hormonal, or monogenic forms of 
hypertension underwent further diagnostic evaluation 
and were not enrolled in the study. Subjects with abnor-
malities in urinalysis, blood tests (creatinine, urea, uric 
acid, electrolytes), and/or renal ultrasonography needed 
additional procedures like renoscintigraphy and/or 
cystourethrography to establish a diagnosis; they were 
classified as patients with renal hypertension. Subjects 
Introduction 
There is growing concern about elevated blood pres-
sure in children and adolescents. Until recently it was 
thought that secondary forms of hypertension domi-
nate in youth, but recent reports show the increasing 
prevalence of primary hypertension among paediatric 
patients [1]. Despite constant scientific progress, it 
still seems to be a challenge to reveal the mechanisms 
underlying hypertension. Hypertension has been 
considered to be a low-grade inflammatory condition 
characterised by the presence of various cytokines [2]. 
Tumour necrosis factor alpha (TNF-a) is a constituent 
of proinflammatory cytokines reported to be engaged 
in alterations of endothelial function in hypertension 
[3, 4]. TNF-α, by its influence on diminished nitric oxide 
bioavailability, acts itself as a vasoconstrictor, but it also 
initiates endothelin-1 (ET-1) release [5]. ET-1, a product 
of endothelial cells, shows positive paracrine impact 
on vascular tone [6]. ET-1 seems to be a marker of en-
dothelial engagement in hypertension. Unfortunately, 
scientific data on ET-1 concentrations in hypertensive 
patients are not consistent [7]. Endothelial hyperre-
activity in hypertension, leading to vasoconstriction, 
can be potentially balanced by mechanisms based on 
the promotion of natriuresis and vasorelaxation. Atrial 
natriuretic peptide (ANP) is a factor that stimulates both 
processes. The literature shows that plasma concentra-
tions of ANP can be increased in hypertension [8]. Cur-
rent studies concentrate on markers of endothelial func-
tion in hypertensive adults; investigations depicting 
children are scarce. Because in the paediatric population 
the increasing phenomenon of primary hypertension is 
incontestable, there is still a vast proportion of patients 
with hypertension of renal origin induced by global or 
segmental renal blood flow impairment. Aiming to get 
better view in the process of inflammation and endo-
thelial contribution in hypertension of the young, we 
compared serum concentrations of TNF-a, ET-1, and 
N-terminal fragment of pro-atrial natriuretic peptide 
(NTpro-ANP) in children with primary hypertension, 
renal hypertension, and normotensive controls.
Material and methods
Study sample
The study was performed among children referred to 
the Division of Paediatric Nephrology in Zabrze due to 
a history of elevated blood pressure from August 2016 
Wnioski: Istotnie wyższe stężenia ET-1, NT-pro ANP oraz TNF-a u dzieci w nadciśnieniu tętniczym pierwotnym oraz nerkopochodnym 
wskazują na znaczenie zaburzeń równowagi śródbłonkowej w rozwoju choroby nadciśnieniowej w wieku rozwojowym. (Endokrynol 
Pol 2019; 70 (1): 38–42)
Kluczowe słowa: nadciśnienie tętnicze; dzieci; endotelina 1; czynnik martwicy nowotworu alfa; przedsionkowy peptyd natriuretyczny
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with no abnormalities, apart from disturbances typical 
for metabolic syndrome, were classified as patients with 
primary hypertension. 
The study comprised 63 hypertensive subjects aged 
13.56 ± 3.73, range 2.0–18.0 years, with a diagnosis of 
primary hypertension (50 patients, aged 14.09 ± 3.77, 
range 2.0–17.9 years) and renal hypertension (13 pa-
tients, aged 13.6 ± 2.68, range 9.9-18.0 years: six with 
renal hypodysplasia, four with ectopic kidney, and 
three with reflux nephropathy). Younger children (un-
der 10 years of age) made up 14.3% of the study group 
(7 out of 50 children (14%) with primary hypertension, 
2 out of 13 children (15.4%) with renal hypertension). 
None of the participants was administered hyperten-
sive drugs prior to the entry to the study. The control 
group consisted of 34 subjects, aged 12.76 ± 3.96, range 
6.25–17.75 years with normal office BP according to 2016 
European Society of Hypertension guidelines measured 
with the validated oscillometric method with use of 
an IntelliVue MX700 device. Younger children (under 
10 years of age) made up 17.6% of the control group (6 
out of 34 children). The study protocol was approved 
by the Silesian Medical University Bioethical Committee 
and all the participants’ parents as well as participants 
aged 16 years and older provided written, informed 
consent. Participants underwent routine medical his-
tory, measurements of height and weight, and labora-
tory assessment.
Medical history and clinical evaluation 
All those surveyed had a negative medical history for 
chronic diseases and chronic medication as well as for 
any acute infectious disease or major trauma within 
two weeks prior to the enrolment. Subjects’ parents 
completed an interview aimed at obtaining information 
about family history of hypertension, and/or diabetes, 
and/or cardiovascular events, and perinatal history 
of the participants regarding prematurity and birth 
weight. Body mass index (BMI) was calculated as weight 
(kilograms) divided by the square of the height (metres). 
BMI was referred to the sex-specific BMI-for-age growth 
charts provided by the World Health Organisation for 
children under five years old and by OLAF for children 
at the age of 5–18 years [15]. BMI was presented as 
a percentile value.
Laboratory assessment
After overnight fasting, blood samples obtained by 
venepuncture were collected. Measurements of serum 
concentrations of c-reactive protein (CRP), glucose, 
creatinine, uric acid, sodium, potassium, bicarbon-
ate, total cholesterol, high-density lipoprotein (HDL) 
cholesterol, low-density lipoprotein (LDL) cholesterol, 
and triglycerides were performed. The estimated glo-
merular filtration rate (GFR) was calculated according 
to the Schwartz formula [16].
Blood samples for the measurement of serum con-
centrations of ET-1, NT-pro ANP, and TNF-a were cen-
trifuged and serum specimens were stored at –70°C until 
analysis. Concentrations of ET-1 were measured using 
an ELISA kit (Cloud-Clone Corp., Houston, TX, USA) 
with an inter-assay variation below 12% and intra-assay 
variation below 10%. Serum concentrations of NT-pro 
ANP were measured using an ELISA kit (Cloud-Clone 
Corp., Houston, TX, USA) with an inter-assay variation 
below 11% and intra-assay variation below 9%. Serum 
concentrations of TNFa were measured using an ELISA 
kit (TNFa Hu 950.090.096, Diaclone SAS, France) with 
an inter-assay variation below 7.8% and intra-assay 
variation below 5.4%.
Statistical analysis
Database management and statistical analysis were 
performed with the STATISTICA data analysis soft-
ware system (version 12, StatSoft, Inc.). Comparisons 
between the group with primary hypertension, the 
group with normal blood pressure, and the group with 
renal hypertension were performed for qualitative and 
quantitative variables. Proportions were compared 
using the c2 test. Quantitative variables were analysed 
for normal distribution by the Shapiro-Wilk test. On 
account of distribution drifting away from normal, 
U Mann-Whitney test was performed to compare 
quantitative variables. P-values < 0.05 were considered 
statistically significant.
Results
Baseline and biochemical characteristics of study 
samples are shown in Tables I–III. Significantly higher 
BMI percentile values in patients with primary hy-
pertension when compared to patients with renal 
hypertension and normal blood pressure were ob-
served (p = 0.004 and p < 0.001, respectively). There 
was a significant increase in serum CRP (p = 0.005), 
triglycerides (p = 0.026), and uric acid (p < 0.001) 
and a decrease in HDL levels (p = 0.034) in primary 
hypertensive subjects compared to normotensive 
controls. In the comparison between groups with 
primary and renal hypertension, significantly higher 
uric acid (p = 0.018) and lower HDL (p < 0.001) serum 
concentrations were observed in primary hypertensive 
participants. Serum concentrations of ET-1, NT-pro 
ANP, TNF-α in study samples are shown in Table IV. 
ET-1 levels were significantly higher in children with 
primary hypertension (9.93 ± 1.73 pg/ml) and renal 
hypertension (10.77 ± 1.50 pg/ml) in comparison to 
controls (4.03 ± 0.97 pg/ml), (p<0.001, p<0.001, respec-
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tively). NT-pro ANP concentrations in patients with 
primary hypertension (71.03 ± 10.02 pg/ml) and renal 
hypertension (84.78 ± 6.44 pg/ml) were significantly 
higher than in a control group (29.62 ± 5.56 pg/ml), 
(p < 0.001, p < 0.001, respectively). TNF-a con-
centrations in subjects with primary hypertension 
(8.36 ± 1.60 pg/ml) and renal hypertension (7.35 ± 0.93 
pg/ml) significantly exceeded concentrations in con-
trols (4.49 ± 0.93 pg/ml), (p < 0.001, p < 0.001, respec-
tively). ET-1 and NT-pro ANP concentrations in chil-
dren with renal hypertension significantly exceeded 
analogous concentrations in a group with primary 
hypertension (p = 0.049, p < 0.001 respectively) while 
TNF-a levels in patients with renal hypertension were 
significantly lower than in a group with primary hy-
pertension (p = 0.046).
Table I. Baseline characteristics of the study sample for quantitative variables
Tabela I. Charakterystyka badanych grup pod względem wybranych parametrów jakościowych
Primary hypertension 
(n = 50)
Normal blood pressure 
(n = 34)
Renal hypertension 
(n = 13)
p value p value p value
Mean SD Mean SD Mean SD 1 vs. 2 1 vs. 3 2 vs. 3
Age [years] 
(min.–max.)
14.09 
(2.0–17.9)
3.77 12.76 
(6.25–17.75)
3.96 13.60 
(9.9–18.0)
2.68 0.127 0.312 0.712
BMI percentile 89.16 17.33 72.85 26.25 73.00 24.53 0.004 < 0 .001 0.625
Birth weight [g] 3328.40 612.72 3490.29 635.23 3005.39 708.49 0.407 0.124 0.072
BMI — body mass index; SD — standard deviation
Table II. Baseline characteristics of study samples for qualitative variables
Tabela II. Charakterystyka badanych grup pod względem wybranych parametrów ilościowych
Primary hypertension  
(n = 50)
Normal blood pressure 
(n = 34)
Renal hypertension  
(n = 13)
p value p value p value
n % n % n % 1 vs. 2 1 vs. 3 2 vs. 3
Positive family history for 
hypertension and/or diabetes 
and/or cardiovascular events
31 62.0% 5 14.7% 4 30.8% < 0.001 0.088 0.402
Prematurity 5 10.0% 1 2.9% 1 7.7% 0.423 0.781 0.932
Table III. Biochemical characteristics of study samples
Tabela III. Charakterystyka badanych grup pod względem wybranych parametrów biochemicznych
Primary hypertension 
(n = 50)
Normal blood pressure 
(n = 34)
Renal hypertension  
(n = 13)
p value p value p value
Mean SD Mean SD Mean SD 1 vs. 2 1 vs. 3 2 vs. 3
Na [mmol/l] 140.20 1.73 140.32 1.79 140.85 1.99 0.565 0.244 0.412
K [mmol/l] 4.50 0.29 4.45 0.27 4.30 0.26 0.243 0.034 0.168
HCO3 (mmol/l) 24.00 2.34 23.15 1.83 24.21 1.75 0.113 0.832 0.101
GFR [ml/min/1,7] 97.81 20.06 102.32 18.30 85.09 14.35 0.177 0.052 0.005
Uric acid [umol/l] 360.56 72.21 284.94 72.32 311.54 49.77 < 0.001 0.018 0.096
Glucose [mg/dl] 92.25 6.01 91.67 5.19 91.20 6.25 0.362 0.288 0.552
Cholesterol [mmol/l] 4.05 0.62 4.15 0.66 4.32 0.78 0.529 0.270 0.643
LDL [mmol/l] 2.31 0.60 2.32 0.65 2.28 0.74 0.799 0.604 0.576
HDL [mmol/l] 1.16 0.26 1.28 0.29 1.60 0.58 0.034 < 0.001 0.032
CRP (mg/l) 1.38 1.33 0.87 1.04 0.91 1.12 0.005 0.070 0.972
Triglycerides [mmol/l] 1.28 0.58 1.08 0.83 1.14 0.52 0.026 0.455 0.385
N — sodium; K — potassium; HCO3 — hydrogencarbonate; GFR — glomerular filtration rate; LDL — density lipoprotein; HDL — high density lipoprotein; 
CRP — C-reactive protein; SD — standard deviation
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Discussion
We investigated biomarkers of inflammation and en-
dothelial function in conditions of hypertension and 
normotension in children and adolescents. The vast 
majority of participants of the study were children at 
pubertal age, which reflects the typical age distribution 
for youngsters with newly diagnosed hypertension. We 
identified a statistical link between elevated levels of 
TNF-a, ET-1, NT pro-ANP, and primary hypertension 
as well as hypertension of renal origin. 
TNF-a, a pro-inflammatory cytokine that is a prod-
uct of macrophages, lymphocytes, and endothelial 
cells, by its influence on nitric oxide synthase mRNA, 
leads to the decrease in bioavailability of nitric oxide, 
which causes vasoconstriction [3, 4]. The results of our 
study demonstrate significantly higher concentrations 
of TNF-a in hypertensive participants than in normo-
tensive ones, which indicates the role of inflammation 
in primary hypertension and renal hypertension. 
Significantly higher levels of TNF-a in participants 
with primary hypertension than in participants with 
renal hypertension may point to the causative func-
tion of inflammation in primary hypertension while 
in renal hypertension low-grade inflammation may be 
only a secondary phenomenon. TNF-a, among other 
pro-inflammatory cytokines, regulates CRP production 
[17]. Significantly higher concentrations of CRP in sub-
jects with primary hypertension in comparison to the 
control group tend to confirm the leading position of 
inflammation in essential hypertension. The theory of 
inflammatory pathogenesis of hypertension has been 
postulated in the literature. Wang et al. proved CRP 
to be one of the predictors of pending hypertension 
[18]. Bautista et al. showed in their study a significant 
link between interleukin-6 and TNF-a and high blood 
pressure, while Głowińska et al. indicated an associa-
tion between TNF-a and hypertension and obesity [19, 
20]. The connection between high blood pressure and 
obesity has been well defined [21]. Under circumstances 
of obesity, adipocytes behave like immune cells, able 
to release proinflammatory adipokines and cytokines 
including TNF-a and CRP [22]. The results of our 
survey show that children with primary hypertension 
had significantly higher BMI percentile than children 
with renal hypertension and normal blood pressure, 
which may serve as an explanation for higher TNF-α 
and CRP concentrations. The survey of Zhen et al. 
shows that uric acid inhibits nitric oxide expression 
and induces TNF-a expression, which suggests that 
uric acid induces endothelial inflammation [23]. On the 
other hand, according to Riwanto et al., HDL directly 
stimulates endothelial cell production of nitric oxide as 
well as endothelial repair processes, which causes HDL 
to be an anti-inflammatory factor [24]. In our project 
a group with primary hypertension was characterised 
by significantly higher concentrations of uric acid and 
significantly lower concentrations of HDL. The results 
discussed above acknowledge the position of inflamma-
tion in pathogenesis of hypertension. Endothelium pos-
sesses mechanisms able to maintain balance between 
dilating and constricting factors. ET-1, produced by 
vascular endothelium, acting in a paracrine fashion on 
vascular smooth muscles cells, is one of the best-known 
vasoconstrictors [25]. Although scientific data seem 
not to be consistent, there are studies indicating a link 
between elevated ET-1 levels and hypertension [7, 26]. 
In our study we observed significantly higher plasma 
concentrations of ET-1 in hypertensive participants than 
in normotensive controls. Interestingly, ET-1 concentra-
tions were statistically higher in children with renal 
hypertension than in children with primary hyperten-
sion. ET-1 synthesis and release can be stimulated either 
by vasoactive hormones and shear stress or by free 
radicals and pro-inflammatory cytokines [5]. Probably 
in hypertension of renal origin the renin-angiotensin 
system plays a major role in ET-1 stimulation while 
in primary hypertension ET-1 seems to be dependent 
on low-grade inflammation. There is research indicat-
ing a role of ET-1 in the formation of reactive oxygen 
species and pro-inflammatory cytokines, which can 
potentially explain the pathogenesis of inflammation in 
hypertension of renal origin [27]. ET-1 stimulates ANP 
synthesis. ANP, being the main opponent of ET-1 and 
Table IV. ET-1, NT-pro ANP, and TNF-a concentrations in the study samples
Tabela IV. Stężenie ET-1, NT-pro ANP, TNF-a w badanych grupach
Primary hypertension 
(n = 50)
Normal blood pressure 
(n = 34)
Renal hypertension  
(n = 13)
p value p value p value
Mean SD Mean SD Mean SD 1 vs. 2 1 vs. 3 2 vs. 3
ET-1 [pg/ml] 9.93 1.73 4.03 0.97 10.77 1.50 < 0.001 0.049 < 0.001
NT-pro ANP [pg/ml] 71.03 10.02 29.62 5.56 84.78 6.44 < 0.001 < 0.001 < 0.001
TNF-a [pg/ml] 8.36 1.60 4.49 0.93 7.35 0.95 < 0.001 0.046 < 0.001
ET-1 — endothelin-1; NTpro-ANP — N-terminal fragment of pro-atrial natriuretic peptide; TNF-a — tumour necrosis factor alpha; SD — standard deviation
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the renin-angiotensin system, promotes vasorelaxation, 
diuresis, and natriuresis [28]. In our study we noticed 
significantly higher concentrations of NTpro-ANP 
in hypertensive participants than in normotensive 
ones. Interestingly, NTpro-ANP levels were higher in 
children with renal hypertension when compared to 
children with primary hypertension. If we consider 
conclusions derived from the research of Mussalo et 
al. pointing to higher plasma levels of NT-pro ANP 
in patients with renovascular hypertension than in 
patients with essential hypertension, we can postulate 
that clinical conditions connected with impaired renal 
blood flow evoke more expressive ANP response [9]. 
Conclusions
The results of our study show that ET-1, NT-pro ANP, 
and TNF-a concentrations are increased in hyperten-
sion in children. While in primary hypertension TNF-a 
is much more significant, in renal hypertension ET-1 
and NT-pro ANP dominate. Our investigation indicates 
the significant importance of inflammation and endo-
thelial involvement in hypertension in youths.
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